Full Year Report 2017


Listen to the conference call and presentation of the Full Year Report:

https://tv.streamfabriken.com/alligator-bioscience-q4-2017

“2017 ended on a highly positive note. Results from our ADC-1013 clinical Phase I study provided support for further clinical development, and a 6 MUSD milestone was triggered on the initiation of a combination study with ADC-1013 and one of Janssen’s proprietary PD-1 inhibitors. We have grown considerably as a team this year and have had the pleasure of welcoming 14 new colleagues to Alligator. With our pooled talents and combined efforts, we are well placed to execute on our strategy and goals. Looking back at 2017, I am proud to say that we have delivered all that we promised in the IPO – and more – and I am confident that 2018 will be another exceptional year” said Per Norlén, CEO.

Read the complete report here.